Will America’s growing use of weight-loss drugs result in a blue Christmas for food companies and retailers? That’s arguably one takeaway from a new survey from Numerator, a data and technology company. The report looked at the holiday dining habits of people who are on the GLP-1 drugs, a category of medications, including Ozempic, Saxenda and Trulicity, that help with curbing hunger. The drugs have become increasingly popular over the past year and even Oprah Winfrey just announced she was taking a weight-loss medication, although she didn’t specify which one.
According to Numerator, which surveyed over 400 people who take GLP-1 drugs, 66% of them say it’s important to eat healthy during the holiday. That compares with 52% of those not on the medications. Plus, 52% of the GLP-1 group said they expected to be more health conscious in their holiday dining versus the previous year. That’s compared with 33% of those who aren’t on the drugs. Also see: Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk? Still, the GLP-1 and non-GLP-1 groups were nearly identical when it came to admitting that it’s tough to dine right during the holidays. Specifically, 80% of GLP-1 users and 77% of non-GLP-1 users said their holiday eating habits are less healthy than their eating habits the rest of the year. According to a Wall Street Journal story in October, executives at prominent food manufacturers are facing questions about whether the use of the GLP-1 drugs will have a financial impact. And Nicholas Fereday, an executive with agricultural lender Radobank, told the Journal that the concern should be real, given the fact that two-thirds of Americans are overweight. Rob Sarlls, chief executiv …
Article Attribution | Read More at Article Source
According to Numerator, which surveyed over 400 people who take GLP-1 drugs, 66% of them say it’s important to eat healthy during the holiday. That compares with 52% of those not on the medications. Plus, 52% of the GLP-1 group said they expected to be more health conscious in their holiday dining versus the previous year. That’s compared with 33% of those who aren’t on the drugs. Also see: Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk? Still, the GLP-1 and non-GLP-1 groups were nearly identical when it came to admitting that it’s tough to dine right during the holidays. Specifically, 80% of GLP-1 users and 77% of non-GLP-1 users said their holiday eating habits are less healthy than their eating habits the rest of the year. According to a Wall Street Journal story in October, executives at prominent food manufacturers are facing questions about whether the use of the GLP-1 drugs will have a financial impact. And Nicholas Fereday, an executive with agricultural lender Radobank, told the Journal that the concern should be real, given the fact that two-thirds of Americans are overweight. Rob Sarlls, chief executiv …nnDiscussion:nn” ai_name=”RocketNews AI: ” start_sentence=”Can I tell you more about this article?” text_input_placeholder=”Type ‘Yes'”]